MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
QuidelOrtho Corporation (NASDAQ:QDEL), formerly, Quidel Corp (QDEL) prior to merger with Ortho Clinical Diagnostics
Organization & Developments: Quidel
Parents
QuidelOrtho Corporation (NASDAQ:QDEL), formerly, Quidel Corp (QDEL) prior to merger with Ortho Clinical Diagnostics
Children
*A real-time PCR platform that simultaneously detects influenza A/B, respiratory syncytial virus and SARS-CoV-2 in less than 25 minutes.
*Later acquired by Quidel
*Quidel Corp (QDEL)- DEVELOPS RAPID DIAGNOSTIC TESTS FOR INFECTIOUS DISEASES, WOMEN'S HEALTH AND GASTROINTESTINAL DISEASES.
*The analyzers give electronic results within 15 minute
*The platform has the capacity to expand to a multiplex of 12 assays at one time.
*The Quidel Sofia SARS Antigen FIA test kit, a lateral flow immunoassay, is used with Sofia and Sofia 2 Analyzers in point-of-care settings, such as a doctor’s office or pharmacy.
*The test is expected to be highly accurate and sensitive and will be intended for use in point-of-care settings like small hospitals and urgent care clinics.
*There are currently thousands of Quidel analyzers in place across the United States and HHS has identified this technology for use in nursing homes.
2020: Quidel antigen test to detect COVID-19 and flu gets FDA nod
2020: Quidel claims to have about 40% market share in the influenza testing market.
2020: Quidel is a market leader in rapid diagnostic tests for seasonal respiratory viruses (primarily flu) as well as strep.
2020: Quidel: Priced For A Permanent Pandemic; Recommending A Short
2020: Red-Hot Medical Stock Soars To Fresh High On 15-Minute Coronavirus Test
2022: QuidelOrtho Corporation 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: QuidelOrtho: Gets Covid Test Win, Ortho Cost Synergies Improve_seekingalpha.com
2023: QuidelOrtho: Thoughts After A Tough Time
2024: QuidelOrtho Corporation 2023 Q4 - Results - Earnings Call Presentation
2024: QuidelOrtho: Attractive Valuation Despite Weak Performance
2024: QuidelOrtho: Uncertainty Reigns
2025: QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
Jumps
*Key People: Quidel
Finance & Acquisition: Quidel